Treatment of a Patient with Severe Systemic Sclerosis (SSc) Using CD19-targeted CAR T Cells

van Laar J, Farge D, Sont J, Naraghi K, Marjanovic Z, Larghero J . Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014; 311(24):2490-8. DOI: 10.1001/jama.2014.6368. View

Muller F, Boeltz S, Knitza J, Aigner M, Volkl S, Kharboutli S . CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023; 401(10379):815-818. DOI: 10.1016/S0140-6736(23)00023-5. View

Maher T, Tudor V, Saunders P, Gibbons M, Fletcher S, Denton C . Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2022; 11(1):45-54. DOI: 10.1016/S2213-2600(22)00359-9. View

Mougiakakos D, Kronke G, Volkl S, Kretschmann S, Aigner M, Kharboutli S . CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2021; 385(6):567-569. DOI: 10.1056/NEJMc2107725. View

Khanna D, Furst D, Clements P, Allanore Y, Baron M, Czirjak L . Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017; 2(1):11-18. PMC: 5431585. DOI: 10.5301/jsrd.5000231. View